David F. Mcdermott
Expertise in
15
conditions

Dr. David F. Mcdermott

Internal Medicine | Oncology
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 9, 
Boston, MA 
On Staff At
Expertise in
15
conditions
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 9, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Mcdermott is an Internal Medicine specialist and an Oncologist in Boston, Massachusetts. Dr. Mcdermott is highly rated in 15 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Melanoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy.

His clinical research consists of co-authoring 259 peer reviewed articles and participating in 16 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Weill Medical College Of Cornell University
Residency
Tufts Medical Center
Specialties
Internal Medicine
Oncology
Licenses
Internal Medicine in MA
Board Certifications
American Board Of Internal Medicine
Fellowships
Tufts Medical Center
Hospital Affiliations
Beth Israel Deaconess Medical Center
Languages Spoken
English
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Senior Whole Health
  • MEDICARE-MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Beth Israel Deaconess Medical Center - Hematology/Oncology
330 Brookline Avenue, Shapiro 9, Boston, MA 02215
Call: 617-667-2100

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

A Phase II Trial of Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Patients With Unresectable or Metastatic Melanoma
A Phase II Trial of Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Patients With Unresectable or Metastatic Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Dabrafenib, Trametinib
Study Phase: Phase 2
A Phase I/IB Trial of Abemaciclib Alone or in Combination With MK-6482 in Advanced Renal Cell Carcinoma
A Phase I/IB Trial of Abemaciclib Alone or in Combination With MK-6482 in Advanced Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, MK-6482
Study Phase: Phase 1
A Phase 2 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Advanced Non-Clear Cell Renal Cell Carcinoma
A Phase 2 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drugs: Cabozantinib, Nivolumab, Ipilimumab
Study Phase: Phase 2
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Enrollment Status: Completed
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: June 29, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Enrollment Status: Completed
Publish Date: June 25, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Trebananib
Study Phase: Phase 1
Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)
Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma
A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: NeoVax, Ipilimumab
Study Phase: Phase 1
Phase II Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Phase II Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Bevacizumab, Atezolizumab
Study Phase: Phase 2
A Phase II Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
A Phase II Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma
Enrollment Status: Completed
Publish Date: April 29, 2024
Intervention Type: Drug
Study Drug: TAK-228
Study Phase: Phase 2
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
Enrollment Status: Terminated
Publish Date: April 16, 2024
Intervention Type: Biological
Study Drug: ITIL-168
Study Phase: Phase 2
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Completed
Publish Date: May 01, 2023
Intervention Type: Drug
Study Drugs: Tremelimumab, MEDI3617
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)
Enrollment Status: Completed
Publish Date: March 20, 2023
Intervention Type: Drug
Study Drugs: CB-839, Cabozantinib
Study Phase: Phase 2
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: March 17, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy
Enrollment Status: Completed
Publish Date: June 13, 2019
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Enrollment Status: Terminated
Publish Date: April 30, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 15 Less Clinical Trials

259 Total Publications

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
Journal: CA: a cancer journal for clinicians
Published: September 15, 2025
View All 259 Publications
Similar Doctors
Expertise in
22
conditions
Dr. David A. Reardon
Hematology Oncology | Hematology | Oncology
Expertise in
22
conditions
Dr. David A. Reardon
Hematology Oncology | Hematology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Reardon is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Reardon is highly rated in 22 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Tissue Biopsy. Dr. Reardon is currently accepting new patients.

Expertise in
44
conditions
Dr. Eric D. Jacobsen
Hematology Oncology | Hematology | Oncology
Expertise in
44
conditions
Dr. Eric D. Jacobsen
Hematology Oncology | Hematology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eric Jacobsen is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Jacobsen is highly rated in 44 conditions, according to our data. His top areas of expertise are Peripheral T-Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Jacobsen is currently accepting new patients.

Daniel J. Deangelo
Expertise in
36
conditions
Dr. Daniel J. Deangelo
Hematology Oncology | Oncology | Hematology
Expertise in
36
conditions
Dr. Daniel J. Deangelo
Hematology Oncology | Oncology | Hematology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Deangelo is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Deangelo is highly rated in 36 conditions, according to our data. His top areas of expertise are Systemic Mastocytosis, Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Deangelo is currently accepting new patients.

VIEW MORE Internists

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mcdermott's expertise for a condition
ConditionClose
  • Elite
  • Melanoma
    Dr. Mcdermott is
    Elite
    . Learn about Melanoma.
    See more Melanoma experts
  • Renal Cell Carcinoma (RCC)
    Dr. Mcdermott is
    Elite
    . Learn about Renal Cell Carcinoma (RCC).
    See more Renal Cell Carcinoma (RCC) experts
  • Distinguished
  • Chromophobe Renal Cell Carcinoma
    Dr. Mcdermott is
    Distinguished
    . Learn about Chromophobe Renal Cell Carcinoma.
    See more Chromophobe Renal Cell Carcinoma experts
  • Clear Cell Sarcoma
    Dr. Mcdermott is
    Distinguished
    . Learn about Clear Cell Sarcoma.
    See more Clear Cell Sarcoma experts
  • Familial Wilms Tumor 2
    Dr. Mcdermott is
    Distinguished
    . Learn about Familial Wilms Tumor 2.
    See more Familial Wilms Tumor 2 experts
  • Lung Cancer
    Dr. Mcdermott is
    Distinguished
    . Learn about Lung Cancer.
    See more Lung Cancer experts
  • Wilms Tumor
    Dr. Mcdermott is
    Distinguished
    . Learn about Wilms Tumor.
    See more Wilms Tumor experts
  • WT1-Related Wilms Tumor Syndromes
    Dr. Mcdermott is
    Distinguished
    . Learn about WT1-Related Wilms Tumor Syndromes.
    See more WT1-Related Wilms Tumor Syndromes experts
  • Advanced
  • Bladder Cancer
    Dr. Mcdermott is
    Advanced
    . Learn about Bladder Cancer.
    See more Bladder Cancer experts
  • Familial Pancreatic Cancer
    Dr. Mcdermott is
    Advanced
    . Learn about Familial Pancreatic Cancer.
    See more Familial Pancreatic Cancer experts
  • Muscle Invasive Bladder Cancer
    Dr. Mcdermott is
    Advanced
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
  • Nephrectomy
    Dr. Mcdermott is
    Advanced
    . Learn about Nephrectomy.
    See more Nephrectomy experts
  • Non-Muscle Invasive Bladder Cancer
    Dr. Mcdermott is
    Advanced
    . Learn about Non-Muscle Invasive Bladder Cancer.
    See more Non-Muscle Invasive Bladder Cancer experts
  • Pleuropulmonary Blastoma
    Dr. Mcdermott is
    Advanced
    . Learn about Pleuropulmonary Blastoma.
    See more Pleuropulmonary Blastoma experts
View All 7 Advanced Conditions
  • Experienced
  • Adult Soft Tissue Sarcoma
    Dr. Mcdermott is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Agranulocytosis
    Dr. Mcdermott is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Mcdermott is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Breast Cancer
    Dr. Mcdermott is
    Experienced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Childhood Acute Myeloid Leukemia
    Dr. Mcdermott is
    Experienced
    . Learn about Childhood Acute Myeloid Leukemia.
    See more Childhood Acute Myeloid Leukemia experts
  • Chronic Myelogenous Leukemia (CML)
    Dr. Mcdermott is
    Experienced
    . Learn about Chronic Myelogenous Leukemia (CML).
    See more Chronic Myelogenous Leukemia (CML) experts
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
  1. Homepage
  2. Internists Boston, MA
  3. Dr. David F. Mcdermott
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.